Last reviewed · How we verify

NCT05267691

Pathological Characteristics of Basal Cell Carcinoma

Status unknown Last updated 20 July 2022
What this trial tests

trial testing Excision in Dermatological Tumors in 50 participants. Status unknown.

Timeline
1 January 2017
Primary endpoint
20 March 2022
20 October 2022

Quick facts

Lead sponsorAl-Azhar University
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment50
Start date1 January 2017
Primary completion20 March 2022
Estimated completion20 October 2022
Sites1 location across Egypt

Drugs / interventions tested

Conditions studied

Sponsor

Al-Azhar University

Who can join

Adults 10 to 100, any sex, with Dermatological Tumors. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A hospital based cross-sectional study was conducted from 2017 to February 2021. Clinical history, examination and histopathological variants were collected from medical files and pathology reports. Confirmation of pathology was done in all the patients visiting skin and plastic surgery department with suspected lesions.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Recurrent cutaneous basal cell carcinoma after surgical excision: A retrospective clinicopathological study.
    Hasan A, Rabie A, Elhussiny M, Nasr M, et al · · 2022 · cited 10× · PMID 35734696 · DOI 10.1016/j.amsu.2022.103877

Verify or expand the search:

Other trials of Excision

Trials testing the same drug.

Other Al-Azhar University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05267691.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing